decreases activation of iNKT cells to levels observed in controls and steady state patients without toxicity.
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INTRODUCTION
Invariant NKT (iNKT) cells have been shown to be a significant contributor to the inflammation that promotes and sustains sickle cell vaso-occlusion, and blockade of iNKT cell activation or depletion of iNKT cells decreases pulmonary inflammation and injury in a murine model of sickle cell disease (SCD). 1, 2 In patients with SCD, iNKT cells are both increased in number and activated compared to healthy controls. [1] [2] [3] These findings suggest that iNKT cells orchestrate an inflammatory cascade in SCD.
Engagement of adenosine A 2A receptors (A 2A R) expressed on iNKT cells is a promising strategy for inhibiting their activation. 2, 4 Regadenoson is a selective A 2A R agonist that is FDA approved for use during myocardial imaging. 5 Administered as a bolus dose of 400 µg over 10 seconds for cardiac stress imaging, regadenoson binds to A 2A Rs on coronary artery smooth muscle cells to induce myocardial hyperemia for 2-4 minutes before coronary blood flow begins to return to normal. 5 The vasodilation produced by regadenoson may cause a decrease in blood pressure and reflex tachycardia. Although such cardiovascular toxicities would be a concern in patients with SCD, the anti-inflammatory actions of A 2A Rs occur at an agonist concentration that is 10 to 100-fold lower than the cardiovascular actions, probably owing to a higher expression of A 2A Rs that are induced upon activation of iNKT cells compared to vascular cells. 2, 6 Increased expression of A 2A Rs on iNKT cells may also explain the potent anti-inflammatory effects of A 2A R agonists in SCD mice. 6 Thus, a low-dose infusion of regadenoson has the potential to maintain a drug concentration that allows for a decrease in inflammation while avoiding cardiovascular side effects.
For personal use only. on April 26, 2017 . by guest www.bloodjournal.org From Based on the potent anti-inflammatory activity of A 2A R agonists when given by infusion in murine models, 2, 4 we elected to administer regadenoson as a low-dose continuous infusion during painful vaso-occlusive crises (pVOC). Our goal was to reduce iNKT cell activation during pVOC without affecting cardiovascular function.
Before administering regadenoson to patients with SCD during pVOC, we evaluated patients at steady state to identify a safe dose and duration of infusional regadenoson.
We examined the activation status of circulating iNKT cells and CD3+ T cells before, during and after infusion of the A 2A R agonist regadenoson in 21 adults with SCD at steady state and in 6 who were admitted to the hospital for pVOC. To identify markers of activation in these cells that may be rapidly responsive to A 2A R activation, we analyzed the p65 subunit of nuclear factor-kappa B (phospho-NF-κB p65) and interferon-gamma (IFN-γ), along with A 2A R expression.
METHODS

Study Conduct
A phase 1 dose-seeking and safety trial of regadenoson was conducted in adults 
Dose Selection
To identify a safe and biologically effective dose of regadenoson, a three stage study was designed, with dose escalation confined to the 12 hour infusion in stage 1.
The objective of the study was to examine the effects of A 2A R activation on iNKT cells using the maximum dose of regadenoson that would be tolerated by at least 5 of 6 individuals for 24 hours during a pVOC (see Supplementary information for definitions of steady state and pVOC). Dose limiting toxicity (DLT) was defined as a sustained change in systolic blood pressure For personal use only. on April 26, 2017 . by guest www.bloodjournal.org From Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) was used to measure plasma levels of regadenoson (Advinus Therapeutics) (see Supplementary information for pharmacokinetic methodology).
Statistical Analysis
Laboratory results were analyzed with robust methods (median, range).
Comparisons of iNKT cell activation parameters between controls and patients at steady state and during pVOC were performed. Direction of differences was hypothesized a priori and one-sided Wilcoxon rank sum (non-paired) and Wilcoxon sign rank (paired) tests were 
RESULTS
Study Participants
Twenty-seven adults with HbSS from the five participating centers were administered regadenoson (Table 1) respectively; however, these changes did not achieve statistical significance.
Pharmacokinetics of Infusional Regadenoson
Increasing dose levels of regadenoson achieved commensurate higher plasma levels of regadenoson during the 12 hour infusion in stage 1 (Figure 3) . Median peak plasma at 1.44 mcg/kg/hour was 1.9 ng/ml (range 0.77-2.74).
Infusional Regadenoson at the Target Dose is Safe in Adults in SCD
Infusional regadenoson at 0.24, 0.60 and 1.44 mcg/kg/hour was safe in adults with SCD. One putative dose limiting toxicity was observed in a baseline participant at dose level 1. The study participant had a brief episode of bradycardia (HR=49 bpm) without a decrease in systolic blood pressure after the infusion was completed and while sleeping. At that point in the study, the threshold for a DLT was less than 50 bpm. Per recommendations of the study cardiologist and data safety monitoring board, the threshold was thereafter changed to 40 bpm to avoid capturing normal physiologic variation. No other dose limiting toxicities were observed in study participants at any dose level. In particular heart rate and blood pressure were relatively stable throughout the regadenoson infusion 
DISCUSSION
This study demonstrates that during pVOC iNKT cells increase numerically in the blood, become more activated and express higher levels of A 2A Rs compared to controls and steady state adults with SCD. The increased iNKT cell activation during pVOC can be In other studies, we discovered that phospho-NF-κB p65 expression in iNKT cells provides the most reliable index of rapid changes in iNKT cell activation in response to regadenoson. 6 Based on these results, we focused on phospho-NF-κB p65 expression in the current study to determine iNKT cell activation status in different disease states (steady state, pVOC) and pre-and post-regadenoson infusion. We found that phospho-NF-κB p65 For personal use only. on April 26, 2017 . by guest www.bloodjournal.org From presentation is restricted to antigen presenting cells expressing the major histocompatibility complex 1-like CD1d receptor. 8, 9 In patients with SCD, glycolipids generated from the tissue damage that occurs during the process of vaso-occlusion are likely activating iNKT cells, although certain host CD1d-restricted lipid antigens can be synthesized by macrophages. 9 Following activation, iNKT cells rapidly secrete large amounts of cytokines and propagate a generalized leukocyte inflammatory response via IFN-γ-inducible chemokines and the activation and recruitment of T cells, NK cells, neutrophils and macrophages. 10, 11 Owing to their rapid activation and stimulation of a broader inflammatory response, iNKT cells are thought to be important instigators of inflammation despite representing only 0.5% of peripheral blood T cells in healthy subjects. 12 In a prior study of steady state patients with SCD, the number of circulating iNKT cells was about 5 times higher than healthy controls and are more likely to be activated. 1 Data from this study and another from our group demonstrates that during a pVOC, there is a further increase in number and activation of iNKT cells. 6 Together with the SCD murine data implicating iNKT cells in the process of vaso-occlusion 1, 2 , these data provide further evidence for the role of iNKT cells in SCD morbidity. Decreasing iNKT cell activation in patients with SCD has the potential to dampen the severity of pVOC by interrupting the vicious cycle of vasoocclusion, tissue injury/inflammation and further vaso-occlusion that characterizes the pathogenesis of pVOC. Although infection is a concern when blocking iNKT cell activation, the approach used in this study minimizes the risk due to the short duration of treatment (24 hours) and half-life of regadenoson (~5 minutes).
In the current study of patients with SCD, we discovered that phospho-NF-κB p65 is highly responsive to A 2A R activation on iNKT cells, rapidly reflecting changes in iNKT cell activation status. NF-κB is a transcription factor that promotes inflammation, in addition to having roles in cell survival and cell death. 13 Signaling through the NF-κB pathway is crucial for iNKT cell proliferation and cytokine production. 14 18 and monocytes, 19, 20 in addition to iNKT cells, and increased levels of numerous cytokines when pVOC and steady state are compared. 21, 22 These previous studies show that inflammation in vaso-occlusion is multi-cellular in origin
and not confined to a single signaling pathway, presenting a challenge when identifying therapeutic interventions. 23, 24 iNKT cell activation, however, is an early event in immune response and may incite this cascade of multi-cellular activation and cytokine production that leads to the widespread inflammation in vaso-occlusion.
Adenosine signaling through the A 2B receptor has been associated with priapism and red cell sickling in murine models of SCD. [25] [26] [27] Although these findings have not been confirmed in patients with SCD, the data underscore the importance of the selectivity of regadenoson for the A 2A R. In the current study, regadenoson produced A 2A R-mediated anti-inflammatory effects in the absence of potential toxicities such as bradycardia and bronchospasm that could have been induced through A 1 and A 2B receptor signaling, respectively. These data support the notion that regadenoson is selective for A 2A R at the plasma levels achieved in our study.
Limitations were present in this study. The key finding that regadenoson decreased activation of iNKT cells is based on sampling the circulating iNKT cell population. Upon activation, iNKT cells are recruited to sites of inflammation and marginate to the walls of blood vessels or emigrate out of the vasculature and into the surrounding tissues. Since activated iNKT cells migrate out of the vasculature, our results may under-estimate the degree of activation and potentially the response of iNKT cells to regadenoson. The highest dose that we examined was not the maximally tolerated dose since no toxicities attributable to the drug occurred during the study. However, we anticipate that due to > 100-fold upregulation of A 2A Rs on iNKT cells, a 2 ng/ml plasma concentration of regadenoson is sufficient for maximal effects of A 2A R activation. 6 In fact, the target dose of 1.44 mcg/kg/hour decreased iNKT cell activation to levels similar to healthy controls. An alternative explanation for the effect of regadenoson on iNKT cell activation during pVOC is that the infusions were coincident with resolving crises and decreasing inflammation.
However, in data presented separately, decreases in iNKT cell activation also occurred during dose-seeking stage 1 when regadenoson was administered to steady state patients, suggesting that the observed reduction in iNKT cell activation during pVOC was due to the actions of regadenoson as opposed to improving vaso-occlusion. 6 Finally, this study was For personal use only. on April 26, 2017 . by guest www.bloodjournal.org From
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